Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
INACTIVE COMPANY
 
My Lists

Zyomyx

6519 Dumbarton Circle
Fremont, CA 94555
USA
510-265-8000
Website Company Summary Management Team
Team

Management: Peter Wagner (CEO)
Outside board: R. Michael Richey (diaDexus Chief Business Officer) Mark Mitchnick (Credit Suisse First Boston Private Equity) Craig C. Taylor (Alloy Ventures)
Company

Business description: Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.
Customers include: Aventis;  GlaxoSkithKline;  Invitrogen;  National Eye Institute
Partners include: Axon InstrumentsBD BiosciencesDyaxGlaxoSmithKline;  Biosciences;  Cambridge Antibody Technology;  Fujirebio;  MDS Proteomics;  Partners Healthcare;  Specialty Laboratories
Capital

Rounds: 6
Recent fundings: Jul 2013   Feb 2004
Capital raised: 113.2M
Last Round: 12.0M
Ownership: Private  
VCs include: Alafi CapitalAlloy VenturesCredit SuisseHambrechtAndQuist Capital ManagementLilly BioVenturesMediphase Venture PartnersMobius Venture CapitalNIF VenturesSkyline Ventures;  511 Equities;  CE Capital Life Sciences;  Technology Finance;  Yasuda Enterprise Development
Corporate investors: GE EquityMylanSumitomo;  Invus;  MDS Proteomics;  Singapore Bio-Innovation of America;  Yasuda Enterprise Development
Other investors: BillAndMelinda Gates Foundation

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2013
Sector: Biotech
Year Founded: 1998
Rounds: 6
Recent fundings: Jul 2013   Feb 2004
Capital raised: 113.2M
Last Round: 12.0M
Ownership: Private